Opioid Use Disorder

New England CEPAC

Opioid use disorder has reached a critical level in the United States, driven by over-prescription and diversion of opioid painkillers, as well as the low cost and increased potency of heroin. The societal impact is substantial in terms of costs related to treatment, lost work productivity, criminal activity, and social welfare expenditure.  The goals of treatment for opioid use disorder include a decrease in illicit opioid use, decreased mortality, and reductions in criminal activity.

Interventions of interest, 2018 review:

Medications for addiction treatment using:

  • Monthly buprenorphine injection (Sublocade™, Indivior)
  • Buprenorphine implant (Probuphine®, Braeburn/Titan)
  • Buprenorphine extended release injection (CAM2038, Braeburn) currently under review by the FDA

These therapies will be compared to MAT with methadone, buprenorphine/naloxone sublingual film (Suboxone®, Indivior), and injectable naltrexone (Vivitrol®, Alkermes).

A 2014 review assessed MAT with methadone or buprenorphine-containing agents (Subutex®, Reckitt Benckiser Pharmaceuticals Inc.; Suboxone®, Indivior Inc.); dose-tapering strategies for methadone or Suboxone, with or without naltrexone (Revia®, Duramed Pharmaceuticals, Inc.; Vivitrol®, Alkermes, Inc.); use of naltrexone alone without prior stabilization on methadone or buprenorphine; and drug-free opioid withdrawal management.

ASSOCIATED MEETING & MATERIALS

New England CEPAC
November 8, 2018 10am - 4pm ET

Newton Marriott
2345 Commonwealth Avenue
Newton, MA 02466

The New England CEPAC will convene to review evidence on medications for addiction treatment in opioid use disorder.

Key Dates

Associated Materials

04/05/2018 – 04/23/2018
Open Input Period

04/26/2018

04/26/2018

04/26/2018 – 05/16/2018

For more information about submitting a public comment, including formatting specifications, please see our engagement page.


05/24/2018

06/29/2018

07/25/2018

09/07/2018

09/07/2018

09/07/2018 – 10/04/2018

For more information about submitting a public comment, including formatting specifications, please see our engagement page.


10/25/2018

10/25/2018

10/25/2018

10/25/2018

11/08/2018

12/03/2018
Report-at-a-Glance

12/03/2018
Final Evidence Report and Meeting Summary


ASSOCIATED MEETING & MATERIALS

New England CEPAC
June 20, 2014 10:00AM-4:00PM

University of Vermont, Burlington, VT

Key Dates

Associated Materials

06/09/2014

06/09/2014

06/20/2014

06/20/2014

06/27/2014

Public comments received on the Draft Evidence Report.


07/21/2014

07/21/2014

07/21/2014
Action Guide For Patients

07/21/2014
Action Guide For Clinicians

07/21/2014
Action Guide For Payers and Policymakers